This is a $249,334 firm fixed-price purchase order awarded by the National Institute on Aging (NIA) to Scantox Neuro GMBH, a for-profit organization based in Austria. The contract supports pharmacodynamic and tolerability studies of candidate Alzheimer's disease (AD) drugs using a transgenic AD mouse model. This work builds on NIA's ongoing efforts under the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) and Experimental Validation of Candidate Alzheimer's Disease Treatments...
This is a $199,812 firm fixed price purchase order awarded by the National Institutes of Health's (NIH) National Institute on Aging (NIA) to QPS Austria GMBH, a contract research organization. The contract is for in vivo efficacy studies of a candidate Alzheimer's treatment in a transgenic mouse model. This award is part of the NIA's Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study, which aims to identify FDA-approved drugs that may be repurposed as disease-modifying...
The Department of Health and Human Services' National Institutes of Health National Institute on Aging has awarded a $830,053.00 firm fixed price delivery order contract to QPS Austria GMBH, a contract research organization, to conduct experimental validation of candidate Alzheimer's disease treatments identified through multi-omics analyses. This delivery order is part of a larger indefinite delivery contract with QPS Austria GMBH to provide these services, with a potential total value...
<p>The National Institutes of Health National Institute on Aging, within the Department of Health and Human Services, awarded a $638,000 firm fixed price delivery order contract to QPS Austria GmbH. The contract is for experimental validation of candidate Alzheimer's disease treatments identified through multi-omics analyses. The period of performance is from June 1, 2022 through May 31, 2023, with all work to be conducted in Austria by QPS Austria GmbH as the prime contractor.</p>
The Department of Health and Human Services' National Institutes of Health National Institute on Aging awarded a $298,624 firm fixed-price purchase order to QPS Austria GmbH to provide phenotypic screening services to identify effective treatments for Alzheimer's disease. The requirement, as outlined in the solicitation, is for the contractor to test approximately 20 FDA-approved drugs that have been nominated as potential treatments in order to determine if exposure is associated with lower...
<p>The U.S. National Institute on Aging, a civilian federal agency, awarded a $21,787.50 firm fixed-price purchase order contract to Scantox Neuro GMBH, a for-profit organization, to provide reagent materials including hydroxychloroquine sulfate and related chiral separation/purification products. The contract has a period of performance through January 22, 2025 and was awarded on December 23, 2024 with no set-aside designation.</p>
This is a firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Aging to the National University of Singapore. The $169,830 contract is for testing the efficacy of candidate Alzheimer's disease treatments in rescuing impaired hippocampal synaptic plasticity. This is part of the NIH's Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study, which is testing approximately 20 FDA-approved drugs to...
The National Institutes of Health (NIH) Intramural Center for Alzheimer's and Related Dementias (CARD) awarded a $1,358,471.01 firm-fixed-price purchase order to Government Scientific Source Inc. for a High-Content Screening System (Opera Phenix Plus or equivalent). This equipment will support the Induced Pluripotent Stem Cell Neurodegenerative Disease Initiative (iNDI) project, which aims to measure how neurodegeneration-related mutations alter protein networks in disease-relevant cell...
This is a $5,724,344 federal contract award issued by the National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL). The contract is a delivery order under the larger "Manufacturing and Nonclinical Studies Support for the Development of Therapeutic Biotechnology Products for Neurological-related Disorders" Indefinite Delivery Vehicle (IDV), which has a total ceiling value of $149.2...
The National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institutes of Health (NIH), awarded a $199,184 firm-fixed-price purchase order to the California Institute of Technology (Caltech), through its Jet Propulsion Laboratory division, to provide biochemical, biophysical, and in vivo testing of up to 100 compounds. This contract supports NINDS's drug discovery campaign to develop novel therapeutics for Alzheimer's disease and related dementias, specifically...
This federal contract award to Scantox Neuro GMBH, a for-profit organization based in Austria, is for $249,000.00 to conduct tolerability studies of candidate Alzheimer's disease (AD) drugs and evaluate the efficacy of poly(L-lysine succinylated)-hydroxychloroquine (PLS-HCQ) in a transgenic AD mouse model. The award is part of the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) and Experimental Validation of Candidate Alzheimer's Disease Treatments Identified by Multi-Omics Analyses (PREVENT-AD) studies conducted by the National Institute on Aging (NIA) Intramural Research Program (IRP). This firm fixed-price purchase order contract has a period of performance from September 30, 2022 to May 2, 2025, and was not set aside for a specific business type. The contract is associated with a larger $2,326,159.08 Indefinite Delivery Contract (IDC) awarded to Scantox Neuro GMBH by the NIA to support experimental validation of potential AD treatments.